TP53 alterations have found to be associated with more rapid drug resistance, irrespective of the underlying mechanisms, resulting in decreased PFS and OS in patients with EGFR-mutant NSCLC [27]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.